Yes, Yervoy Has Caused Deaths from Side Effects
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, carries a black box warning for severe immune-related adverse events that can lead to death. These include immune-mediated reactions like colitis, hepatitis, endocrinopathies, pneumonitis, and dermatitis, which occur because the drug boosts T-cell activity against tumors but can also attack healthy tissues.[1]
Key Cases and Clinical Data on Fatal Outcomes
In clinical trials, fatal immune-related adverse reactions happened in 1.1% of Yervoy-treated patients (7 of 639). Causes included gastrointestinal perforation, hepatitis, pneumonitis, and myocarditis. Post-marketing reports document additional deaths from enterocolitis (leading to bowel perforation), severe skin reactions like Stevens-Johnson syndrome, and myocarditis.[1][2]
Real-world data from the FDA's Adverse Event Reporting System (FAERS) shows over 200 U.S. death reports linked to Yervoy as of 2023, often involving multi-organ failure or infections secondary to immune suppression from treatment.[3] A 2014 study in the New England Journal of Medicine analyzed 1,196 patients and found 1% mortality from adverse events, mostly colitis-related.[4]
How Often Do Deaths Occur and Who Is at Risk?
Deaths are rare—under 2% in trials and observational studies—but rise with combination therapy like Yervoy plus Opdivo (nivolumab). Risk factors include prior autoimmune disease, older age (>65), and higher doses. Early intervention with steroids or infliximab reduces fatality risk, but delays can be lethal.[1][5]
| Scenario | Fatal Event Rate |
|----------|-----------------|
| Yervoy monotherapy | ~1% [1] |
| Yervoy + Opdivo | 1.3-2.2% [6] |
| Post-approval reports | Higher in frail patients [3] |
What Happens If Side Effects Escalate?
Severe colitis can cause toxic megacolon or perforation within weeks of starting treatment. Pneumonitis may require ventilation, and hepatitis can lead to liver failure. Patients report symptoms like persistent diarrhea, rash, or fatigue—prompt medical attention is critical, as 85% of severe cases resolve with immunosuppression.[1][2]
Patient Experiences and Warnings
Survivor accounts on forums like Cancer Research UK note near-fatal colitis resolved after hospitalization, but families of deceased patients cite inadequate monitoring. The label mandates baseline tests and weekly checks for the first cycles.[1] Oncologists screen high-risk patients and discontinue at grade 3+ toxicity.
Sources
[1]: Yervoy Prescribing Information (FDA)
[2]: Drugs.com - Yervoy Side Effects
[3]: FAERS Public Dashboard (FDA)
[4]: Hodi et al., NEJM (2014) - PubMed
[5]: ASCO Guidelines on Immunotherapy Toxicity
[6]: Opdivo + Yervoy Label (FDA)